Shuttle Pharmaceuticals Holdings, Inc. Common Stock

Day range

$4.89 – $5.19

Open

$4.92

Prev close

$4.86

Volume

10.57K

Market cap

$23.16M

Shares out

4.76M

P/E

—

P/S

—

P/B

1.21

P/FCF

—

ROE

-53.5%

ROA

-45.0%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Internal control weaknessOct 22, 2026

  As previously disclosed... the Company identified the following material weaknesses: The Company's written policies and procedures over accounting transaction processing and period end financial close and reporting are limited...; the lack of sufficient review and segregation of duties...; findings related to overall information technology general controls...; and deficiencies in the Company's entity level controls.

• Warrant or conversionSep 16, 2026

  As of September 14, 2026, the Company issued an aggregate of (a) 2,869,595 shares of the Company's common stock ... upon the conversion of certain of its issued and outstanding shares of Series B-1 Preferred Stock and (b) 867,887 shares of Common Stock upon the conversion of certain of its issued and outstanding shares of Series B-2 Preferred Stock.

• Special meeting resultsSep 11, 2026

  On September 9, 2026, Shuttle Pharmaceuticals Holdings, Inc. held a Special Meeting of Stockholders (the "Meeting"). The final results for each of the proposals considered at the Meeting are set forth below.

• Shareholder meeting noticeSep 2, 2026

  Shuttle Pharmaceuticals Holdings, Inc. (the "Company") is announcing the postponement of its previously announced special meeting of stockholders (the "Special Meeting") from its currently scheduled date and time on Thursday, September 3, 2026, at 11:00 a.m. Eastern Time, to its new time on September 9, 2026, at 11:00 a.m. Eastern Time (the "Reconvened Special Meeting"). If you vote your proxy, your vote must be received by 11:59 p.m. Eastern Time on September 8, 2026 in order for your vote to be counted.

• Private placementSep 1, 2026

  Securities Purchase Agreement (the "Securities Purchase Agreement"), which it entered into on April 30, 2026 with certain accredited investors (the "Purchasers"), pursuant to which the Company issued (i) 1,910 shares of Series B-2 convertible preferred stock, par value $0.00001 per share and (ii) common stock purchase warrants (the "PIPE Financing"), which PIPE Financing closed on May 6, 2026;

Days to cover

1.0

Short interest

17.79K

Avg volume

35.13K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• E.F. Hutton & Co. Serves as Exclusive M&A Advisor and Placement Agent on Completed Shuttle Pharmaceuticals–United Dogecoin Merger to Create the Largest Public Dogecoin Miner
  positiveBenzinga· May 7, 2026
• Shuttle Executes LOI with Molecule.ai
  positiveBenzinga· Oct 10, 2025
• Shuttle Pharma Announces Closing of $5.75 Million Underwritten Offering
  positiveBenzinga· Mar 13, 2025
• Shuttle Pharma Provides Third Quarter 2024 Corporate Update
  positiveGlobeNewswire Inc.· Nov 13, 2024
• Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
  positiveBenzinga· Oct 29, 2024